Obesity
-
Professor Liping Zhao: Dysbiosis of the core microbiota is the root cause of human obesity！
The video is available for watching, too. Please visit DrugTimes. Many thanks!~
-
【Product for Licensing】siRNA Therapeutics Targeting INHBE and another target
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
【Product for Licensing】ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
NASDAQ-listed companies are looking for obesity drugs with the potential for weight loss and muscle gain
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
Former Pfizer employees bravely venture into the red ocean of obesity drugs
Ambrosia, like Pfizer, is optimistic about the direction of oral small molecules, but whether it can surpass the front runners is something that still needs more time to verify
-
Try again! Pfizer ‘revives’ its oral GLP-1RA
DrugTimes will present more reports. Please stay tuned
-
What is the Current Landscape of Obesity Drug Development in China?
These presentations indicate that the era of domestically developed GLP-1 drugs for weight loss in China is on the horizon, with significant implications for the future of obesity treatment
-
【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications
If your company is interested in this opportunity, please contact us as soon as possible!
-
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, along with positive topline results from its capsule to tablet PK study. Both studies achieved their primary and secondary objectives
